27.01.2025 19:05
Six scientists from İnönü University and Malatya Turgut Özal University have developed a new treatment method to prevent pleuritis and fluid accumulation. Animal experiments are being conducted in the study, which has entered the patent process.
Six scientists from two universities in Malatya are developing a new treatment method to prevent pleurisy and fluid accumulation in the lungs. Animal experiments have begun for the method that will prevent lung infections and the recurrence of fluid accumulation and lung collapse. The experts from İnönü University and Malatya Turgut Özal University have also initiated the patent application process for the method they developed.
"IT IS CALLED MEDICAL TALC" Prof. Dr. Hakan Parlakpınar stated that when the fluid in the space between the two membranes surrounding the lung, called pleura, accumulates excessively or there are recurrent accumulations, it needs to be drained. Parlakpınar explained that this fluid is drained using various methods, saying, "We call the collapse and deflation of the lung pneumothorax. To prevent pneumothorax or to treat it if it has become chronic, one of the treatments aimed at adhering the pleura is the use of a chemical microparticle agent, which is referred to as medical talc."
PLEURA IS BEING ADHERED Parlakpınar, who stated that he has been working on the new method for about 5 years with Prof. Dr. Burhan Ateş and faculty member İdil Karaca Açarı from Malatya Turgut Özal University, said the following about the developed sterile talc application: "Diseases that cause fluid accumulation in the lungs can originate from cancers in the mesenchymal area. When fluid accumulates in the pleura, the lungs cannot function adequately. There is chronic pneumothorax, meaning the lung collapses. After the fluid in the lung cavity is removed, to prevent recurrence and to allow the lungs to function comfortably, the pleura surrounding the lung needs to be adhered. We do this using a chemical agent in terms of chemical adhesion. When this procedure is performed, the pleura will not fill with fluid again, and due to the lubricating effect of the sterile talc used, the lungs will function smoothly while working.
We call the work for which we have obtained a patent modified talc application. We modified it by adding an antibacterial agent. While sterile talc application is one method, antibiotic application is the second method applied. By using both together, we obtained a structure that enhances each other's effects within the same particle. These were achieved with the principle of kill in the environment and clean in the environment, and a polymer-based microparticle was obtained. Our work continues on experimental animals. There are mandatory tests that need to be done before it can be used in humans. We have entered the patent process abroad."
"IT CAN BE USED EASILY IN INFECTIONS CALLED PLEUREDEZ" Prof. Dr. Süleyman Köytepe pointed out that they have obtained a particle that can be effectively used in pleurisy, stating: "It can be easily used in infections called pleuredez. The particle size was developed with a surface coating that can continuously show antibacterial effect without compromising its own properties. The material we obtained retains its antibacterial properties for a longer time, thus shortening the treatment approach and providing a more effective treatment opportunity. Currently, animal tests are ongoing, and if positive results are obtained, it has a chance to enter the drug literature."